Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized peptide-lipid drug conjugates comprising a neuromedin U NMU2 receptor agonist peptide. They are reported to be useful for the treatment of obesity.

Astrazeneca AB has identified new quinazoline derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of colitis, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, schizophrenia, thrombosis and Alzheimer’s disease among others.

Sea4us - Biotecnologia e Recursos Marinhos Lda. has reported oxazolidone-derived compounds potentially useful for the treatment of chronic pain.

Uppthera Inc. has patented new proteolysis targeting chimera (PROTAC) compounds comprising cereblon E3 ubiquitin ligase-binding moiety covalently linked to Aurora kinase A (AURKA; ARK1)-targeting moiety. They are reported to be useful for the treatment of cancer.

Alterome Therapeutics Inc. has divulged substituted pyrido[4,3-d]pyrimidines acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.

Asieris Pharmaceuticals (USA) Inc. has discovered new antibody-drug conjugates comprising antibodies covalently linked to payloads through linkers.

University of Florida researchers have synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)- and apoptosis regulator Bcl-2-targeting moiety.

Work at Nimbus Salacia Inc. has led to the identification of serine/threonine-protein kinase SIK2 (QIK) inhibitors.

Terns Pharmaceuticals Inc. has reported triazole compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. They are intended for use in the treatment of diabetes, obesity, liver diseases and cardiometabolic syndrome.

Humanwell Pharmaceutical US Inc. has disclosed prodrugs of somatostatin SST4 receptor agonists described as potentially useful for the treatment of visceral and neuropathic pain.